| Literature DB >> 31632023 |
Jia-You Fang1,2,3,4, Yin-Ku Lin5,6, Pei-Wen Wang7, Ahmed Alalaiwe8, Yu-Ching Yang1, Shih-Chun Yang9.
Abstract
BACKGROUND: It is important to explore the interaction between antibacterial nanoparticles and microbes for understanding bactericidal activity and developing novel applications. It is possible that the nanoparticulate size can govern the antibacterial potency.Entities:
Keywords: MRSA; biofilm; cetylpyridinium chloride; nanoemulsion; size effect
Mesh:
Substances:
Year: 2019 PMID: 31632023 PMCID: PMC6790405 DOI: 10.2147/IJN.S221663
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
The Characterization Of Micelles And Cationic Nanoemulsions By Droplet Size, Polydispersity Index (PDI), And Zeta Potential
| Formulation | Size (nm) | PDI | Zeta Potential (mV) |
|---|---|---|---|
| Micelles | 1434.67±102.47 | 1.0±0 | 9.27±2.23 |
| CN-S | 54.54±1.93 | 0.40±0.12 | 46.53±1.86 |
| CN-M | 164.73±1.44 | 0.19±0.05 | 46.37±2.35 |
| CN-L | 244.70±2.36 | 0.26±0.01 | 51.10±0.56 |
Note: Each value represents the mean±SD (n=3).
Figure 1The physicochemical characteristics of micelles and squalene@CPC nanoemulsions: (A) the size change of micelles and nanoemulsions at 50 °C and 75% relative humidity for 14 days; and (B) fluorescence emission of Nile red incorporation in micelles and nanoemulsions for determining molecular environment polarity. The stability data are presented as the mean of four experiments±S.D.
The Minimum Inhibitory Concentration (MIC, µg/mL) And Minimum Bactericidal Concentration (MBC, µg/mL) Of Cetylpyridinium Chloride (CPC) In Micelles And Cationic Nanoemulsions Against Different Strains Of Bacteria
| Strain | Micelles | CN-S | CN-M | CN-L | |
|---|---|---|---|---|---|
| MIC | MRSA | 0.98 | 0.98 | 0.98 | 0.98 |
| 0.49~0.98 | 0.49 | 0.49 | 0.49 | ||
| KM-1 | 0.49~0.98 | 0.49 | 0.49 | 0.49 | |
| KV-2 | 0.49~0.98 | 0.49 | 0.49 | 0.49 | |
| 3.91 | 3.91~7.81 | 3.91~7.81 | 7.81 | ||
| 1.95~3.91 | 3.91 | 1.95~3.91 | 1.95~3.91 | ||
| MBC | MRSA | 1.95 | 1.95 | 1.95 | 0.98~1.95 |
| 0.49~0.98 | 0.98~1.95 | 0.98 | 0.49~0.98 | ||
| KM-1 | 0.98 | 0.98 | 0.98 | 0.98 | |
| KV-2 | 0.98~1.95 | 1.95 | 0.98~1.95 | 0.98 | |
| 3.91 | 7.81 | 7.81 | 7.81~15.63 | ||
| 3.91~7.81 | 7.81~15.63 | 7.81~15.63 | 7.81~15.63 |
Note: KM-1 and KV-2 are the clinical isolates of MRSA and VISA, respectively. Each value represents the mean±S.D. (n=3).
Figure 2Determination of the antibacterial activity of micelles and squalene@CPC nanoemulsions against planktonic MRSA: (A) zone of inhibition measured from agar diffusion assay; (B) morphological changes of MRSA viewed under SEM; and (C) the enlarged images of B. The agar diffusion data are presented as the mean of three experiments±S.D.
Figure 3The live/dead imaging by treatment of micelles and squalene@CPC nanoemulsions against planktonic MRSA: (A) treatment with CPC at 10 μg/mL; and (B) treatment with CPC at 100 μg/mL.
Figure 4Determination of the antibacterial activity of micelles and squalene@CPC nanoemulsions against biofilm MRSA: (A) MRSA CFU inside the biofilm; (B) MRSA CFU outside the biofilm; (C) the three-dimensional images of biofilm visualized by confocal microscopy; (D) the corresponding biofilm green intensity; and (E) the corresponding biofilm thickness. All data are presented as the mean of three experiments±S.D. ***p < 0.001; **p < 0.01; *p < 0.05.
Figure 5The genomic and proteomic profiles of MRSA treated by micelles and squalene@CPC nanoemulsions: (A) analysis of the quality of MRSA genomic DNA by agarose gel electrophoresis; (B) total protein concentration in MRSA; and (C) the protein change of MRSA analyzed by SDS-PAGE and MALDI-TOF/TOF mass. All data are presented as the mean of three experiments±S.D. ***p < 0.001; **p < 0.01; *p < 0.05.
Differentially Expressed Proteins In MRSA Following The Treatments Of Micelles And Cationic Nanoemulsions
| Band No. | Protein | Accession No. | Mw (Da) | Matched Peptides | Coverage % | Ratios To MRSAa,b | Biological Function | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Micelles | CN-S | CN-M | CM-L | |||||||
| 1 | DNA-directed RNA polymerase subunit β | P60279 | 133,409 | 19 | 16% (100) | −2.33 | −3.23 | −8.34 | −3.45 | DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. |
| 2 | DNA-directed RNA polymerase subunit β’ | P60286 | 134,327 | 24 | 24% (115) | −2.78 | −0.71 | −3.57 | −0.64 | DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. |
| 3 | Transketolase | Q6GH64 | 72,235 | 15 | 28% (136) | 0.64 | 2.07 | 1.16 | 2.44 | Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate. |
| 4 | Phosphoenolpyruvate carboxykinase (ATP) | Q8NVZ8 | 59,599 | 26 | 56% (168) | −0.59 | −0.21 | −0.96 | −0.54 | Involved in the gluconeogenesis. Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) through direct phosphoryl transfer between the nucleoside triphosphate and OAA. |
| 5 | Catalase | Q8NWV5 | 51,221 | 14 | 47% (141) | −0.28 | 0.95 | 0.97 | 2.20 | Decomposes hydrogen peroxide into water and oxygen; serves to protect cells from the toxic effects of hydrogen peroxide. |
| 6 | Enolase | P64079 | 46,036 | 14 | 47% (90) | 0.91 | −1.59 | 1.82 | 1.18 | Catalyzes the reversible conversion of 2-phosphoglycerate into phosphoenolpyruvate. It is essential for the degradation of carbohydrates via glycolysis. |
| 7 | Pyruvate dehydrogenase E1 component subunit alpha | P60090 | 36,459 | 7 | 34% (84) | −3.03 | −2.50 | −3.57 | −1.94 | The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO2. |
| 8 | L-lactate dehydrogenase | P65257 | 34,650 | 15 | 58% (96) | −2.33 | −1.87 | −2.22 | −2.21 | Catalyzes the conversion of lactate to pyruvate. Appears to be the primary factor that allows |
| 9 | Cysteine synthase | P63872 | 33,013 | 9 | 45% (84) | −2.86 | −0.27 | −0.31 | −1.85 | O-acetyl-L-serine + hydrogen sulfide = L-cysteine + acetate. |
| 10 | Pyridoxal 5ʹ-phosphate synthase subunit PdxS | P60799 | 32,114 | 8 | 42% (95) | −0.07 | 1.13 | 0.99 | 2.34 | Catalyzes the formation of pyridoxal 5ʹ-phosphate from ribose 5-phosphate (RBP), glyceraldehyde 3-phosphate (G3P) and ammonia. |
| 11 | 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase | P65709 | 26,697 | 24 | 86% (204) | 1.08 | 1.19 | −0.12 | −0.21 | Catalyzes the interconversion of 2-phosphoglycerate and 3-phosphoglycerate. |
| 12 | DUF1642 domain-containing protein | PF07852.6 | 22,691 | 9 | 40% (82) | −1.79 | 1.22 | −0.95 | 1.25 | Protein of unknown function (DUF1642) |
| 13 | Superoxide dismutase [Mn/Fe] 2 | P66832 | 23,098 | 10 | 72% (92) | 1.06 | 1.09 | 1.99 | 1.82 | Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems. |
| 14 | Ferritin, partial | Q7A0H5 | 16,627 | 7 | 52% (112) | 1.04 | 1.78 | 1.55 | 2.17 | Iron-storage protein. |
| 15 | DNA protection during starvation protein 2 | Q8RPQ2 | 16,749 | 9 | 76% (88) | 1.23 | 1.16 | 0.93 | 1.58 | Protects DNA from oxidative damage by sequestering intracellular Fe2+ ion and storing it in the form of Fe3+ oxyhydroxide mineral. |
| 16 | DNA-binding protein HU | Q7A0U9 | 9,606 | 7 | 72% (96) | 1.14 | 1.25 | 1.28 | 1.61 | Histone-like DNA-binding protein which is capable of wrapping DNA to stabilize it, and thus to prevent its denaturation under extreme environmental conditions. |
Notes: aRatios to MRSA indicated the fold changes in protein volume among micelles, CN-S, CN-M, and CN-L versus MRSA samples, respectively. The ratios > 1.0 mean the proteins whose expression levels were increased upon treatments of compounds, while ratios < −1.0 indicate the proteins were downregulated under the exposure to compounds. bAnalyzing the gel images using GeneTools software.